MeSH tree: D12.776.543.750.705.816
Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to other T cells in the tumor ...
Feb 3, 2025
0
29
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy—a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable ...
Jun 12, 2024
0
57
A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the ...
Jun 12, 2024
0
42
Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children's ...
Mar 19, 2024
0
55
BioMed X and the Universitätsmedizin Mannheim (UMM) announced the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The main objective of the collaboration was to understand ...
Feb 6, 2024
0
57
Chimeric antigen receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.
Dec 1, 2023
0
88
CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful. A limiting factor of this otherwise very effective and safe therapy ...
Nov 6, 2023
0
46
A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors ...
Oct 25, 2022
0
89
